Metformin: A Therapeutic Opportunity in Breast Cancer

Towler, 2007, AMP-activated protein kinase in metabolic control and insulin signaling, Circ Res, 100, 328, 10.1161/01.RES.0000256090.42690.05

Inoki, 2003, TSC2 mediates cellular energy response to control cell growth and survival, Cell, 115, 577, 10.1016/S0092-8674(03)00929-2

Inoki, 2002, TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling, Nat Cell Biol, 4, 648, 10.1038/ncb839

Kovacic, 2003, Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart, J Biol Chem, 278, 39422, 10.1074/jbc.M305371200

Horman, 2006, Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491, J Biol Chem, 281, 5335, 10.1074/jbc.M506850200

Kramer, 2006, Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle, Diabetes, 55, 2067, 10.2337/db06-0150

Fisher, 2002, Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin, Am J Physiol Endocrinol Metab, 282, E18, 10.1152/ajpendo.2002.282.1.E18

Um, 2004, Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity, Nature, 431, 200, 10.1038/nature02866

Harrington, 2004, The TSC1–2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins, J Cell Biol, 166, 213, 10.1083/jcb.200403069

Shah, 2004, Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies, Curr Biol, 14, 1650, 10.1016/j.cub.2004.08.026

Lochhead, 2000, 5-Aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase, Diabetes, 49, 896, 10.2337/diabetes.49.6.896

Wijkander, 1998, Insulin-induced phosphorylation and activation of phosphodiesterase 3B in rat adipocytes: possible role for protein kinase B but not mitogen-activated protein kinase or p70 S6 kinase, Endocrinology, 139, 219, 10.1210/endo.139.1.5693

Garton, 1989, Phosphorylation of bovine hormone-sensitive lipase by the AMP-activated protein kinase. A possible antilipolytic mechanism, Eur J Biochem, 179, 249, 10.1111/j.1432-1033.1989.tb14548.x

Baserga, 2003, The IGF-1 receptor in cancer biology, Int J Cancer, 107, 873, 10.1002/ijc.11487

Manning, 2007, AKT/PKB signaling: navigating downstream, Cell, 129, 1261, 10.1016/j.cell.2007.06.009

Johnson, 2002, Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases, Science, 298, 1911, 10.1126/science.1072682

Firth, 2002, Cellular actions of the insulin-like growth factor binding proteins, Endocr Rev, 23, 824, 10.1210/er.2001-0033

O'Connor, 2003, Regulation of IGF-I receptor signaling in tumor cells, Horm Metab Res, 35, 771, 10.1055/s-2004-814166

Wan, 2007, Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism, Oncogene, 26, 1932, 10.1038/sj.onc.1209990

Sell, 1994, Effect of a null mutation of the insulin like factor I receptor gene on growth and transformation of mouse embryo fibroblasts, Mol Cancer Biol, 14, 3604

Lopez, 2002, Elevated levels IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis, Cancer Cell, 1, 339, 10.1016/S1535-6108(02)00055-7

Jones, 2007, Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation, Oncogene, 26, 1636, 10.1038/sj.onc.1209955

Hay, 2004, Upstream and downstream of mTOR, Genes Dev, 18, 1926, 10.1101/gad.1212704

Neshat, 2001, Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR, Proc Natl Acad Sci U S A, 98, 10314, 10.1073/pnas.171076798

Bjornsti, 2004, The TOR pathway: a target for cancer therapy, Nat Rev Cancer, 4, 335, 10.1038/nrc1362

Petroulakis, 2006, mTOR signaling: implications for cancer and anticancer therapy, Br J Cancer, 94, 195, 10.1038/sj.bjc.6602902

Meric-Bernstam, 2009, Targeting the mTOR signaling network for cancer therapy, J Clin Oncol, 27, 2278, 10.1200/JCO.2008.20.0766

Evans, 2005, Metformin and reduced risk of cancer in diabetic patients, BMJ, 330, 1304, 10.1136/bmj.38415.708634.F7

Bowker, 2006, Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin, Diabetes Care, 29, 254, 10.2337/diacare.29.02.06.dc05-1558

Goodwin, 2008, Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions?, J Clin Oncol, 26, 833, 10.1200/JCO.2007.14.7132

Wolf, 2005, Diabetes mellitus and breast cancer, Lancet Oncol, 6, 103, 10.1016/S1470-2045(05)01736-5

Calle, 2004, Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms, Nat Rev Cancer, 4, 579, 10.1038/nrc1408

Renehan, 2006, Obesity and cancer risk: the role of the insulin-IGF axis, Trends Endocrinol Metab, 17, 328, 10.1016/j.tem.2006.08.006

Pollak, 2004, Insulin-like growth factors and neoplasia, Nat Rev Cancer, 4, 505, 10.1038/nrc1387

Yee, 2006, Targeting insulin-like growth factor pathways, Br J Cancer, 94, 465, 10.1038/sj.bjc.6602963

Alimova, 2009, Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro, Cell Cycle, 8, 910, 10.4161/cc.8.6.7933

Zakikhani, 2006, Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells, Cancer Res, 66, 10269, 10.1158/0008-5472.CAN-06-1500

Dowling, 2007, Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells, Cancer Res, 67, 10804, 10.1158/0008-5472.CAN-07-2310

Ben Sahra, 2008, The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level, Oncogene, 27, 3576, 10.1038/sj.onc.1211024

Buzzai, 2007, Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth, Cancer Res, 67, 6745, 10.1158/0008-5472.CAN-06-4447

Jiralerspong, 2009, Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer, J Clin Oncol, 27, 3297, 10.1200/JCO.2009.19.6410

Cusi, 1998, Metformin: A review of its metabolic effects, Diabetes Res, 6, 89

Zhou, 2001, Role of AMP-activated protein kinase in mechanism of metformin action, J Clin Invest, 108, 1167, 10.1172/JCI13505

Alessi, 2006, Lkb1-dependent signaling pathways, Annu Rev Biochem, 75, 137, 10.1146/annurev.biochem.75.103004.142702

Hardie, 2007, AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy, Nat Rev Mol Cell Biol, 8, 774, 10.1038/nrm2249

Krause, 2002, Control of p70 ribosomal protein S6 kinase and acetyl-CoA carboxylase by AMP-activated protein kinase and protein phosphatases in isolated hepatocytes, Eur J Biochem, 269, 3751, 10.1046/j.1432-1033.2002.03074.x

Gwinn, 2008, AMPK phosphorylation of raptor mediates a metabolic checkpoint, Mol Cell, 30, 214, 10.1016/j.molcel.2008.03.003

Hardie, 2008, AMPK and Raptor: Matching Cell Growth with Energy Supply, Mol Cell, 30, 263, 10.1016/j.molcel.2008.04.012

Phoenix, 2009, Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERa negative MDA-MB-435 breast cancer model, Breast Cancer Res Treat, 113, 101, 10.1007/s10549-008-9916-5

Liu, 2009, Metformin induces unique biological and molecular responses in triple negative breast cancer cells, Cell Cycle, 8, 2031, 10.4161/cc.8.13.8814

Hirsch, 2009, Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission, Cancer Res, 69, 7507, 10.1158/0008-5472.CAN-09-2994

Martin-Castillo, 2009, Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology, Ann Oncol, 21, 187, 10.1093/annonc/mdp494

Cazzaniga, 2009, Is it time to test metformin in breast cancer clinical trials?, Cancer Epidemiol Biomarkers Prev, 18, 701, 10.1158/1055-9965.EPI-08-0871

Bailey, 1996, Metformin, N Engl J Med, 334, 574, 10.1056/NEJM199602293340906

Ehrmann, 1997, Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome, J Clin Endocrinol Metab, 82, 524